Partner

Andrew Harrow is a partner in the firm’s Life Sciences group. Andrew advises on a wide range of UK and cross-border transactions including joint ventures, mergers and acquisitions, reorganizations, initial public offerings, and fundraisings for listed and private companies internationally as well as general corporate and capital market matters. He has a particular interest in transactions in the life sciences, healthcare, and technology sectors.

Andrew has been noted for his private equity work in The Legal 500 UK, 2016 and recommended in The Legal 500 UK in 2015, 2017 and 2018 in the field of pharmaceuticals and biotechnology; he was also described as “brilliant” with respect to M&A work.

Prior to joining Goodwin in 2018, Andrew was a partner at Dechert LLP.

Legal Practice Course, 1999, Nottingham Law School; Post-Graduate Diploma in Law, 1998, Nottingham Law School; BA, St. John's College, Oxford